Browse the evidence

GLP-1 receptor agonist treatment is associated with a 10.3% reduction in fat mass (FM) at 6 months, 17.3% at 12 months, and 18.0% at 24 months.

GLP-1RA treatment leads to significant fat mass reduction over 24 months.

GLP-1 receptor agonists produced greater weight loss among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%).

Practitioners should consider gender differences when prescribing GLP-1 receptor agonists for weight loss.

The combination of Cinnamomum cassia (300 mg) and Withania somnifera (150 mg) induced significant weight loss compared to placebo (−2.66% vs. −1.28%, respectively; p = 0.0002).

Practitioners may consider this combination as a low-cost supplement option for enhancing weight loss in overweight and obese patients.

The study suggests that the combination of CC and WS may enhance weight loss in patients on a mildly hypocaloric diet.

This combination may be recommended as a supplement to support weight loss efforts in conjunction with dietary changes.

Obesity is associated with serious health risks and consequences for individuals who are pregnant or want to be pregnant.

Healthcare providers should be aware of the risks obesity poses to pregnant individuals.

GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.

Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.

Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.

Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.

Lifestyle interventions, such as adherence to a Mediterranean diet and weight loss, have proven beneficial for both metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF).

Encouraging patients to adopt a Mediterranean diet and focus on weight loss can be beneficial for managing both MASLD and HFpEF.

Incretin-based therapies induced substantial weight loss, mostly from fat mass.

Practitioners can consider incretin-based therapies as effective options for promoting fat loss in T2D patients.

Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.

Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.

A significantly higher rate of patients from the pure Semaglutide group achieved the ten percent (50.54% vs. 44.64%) and fifteen percent (21.42% vs. 12.78%) weight loss thresholds compared to the compounded Semaglutide group.

Practitioners should note that pure Semaglutide may lead to better outcomes in achieving significant weight loss thresholds.

Lifestyle interventions that include diet, exercise, and behavioral modification have been the foundation for management of obesity.

Practitioners should prioritize lifestyle interventions in obesity treatment plans.

The American Gastroenterological Association recommended adding pharmacologic agents to lifestyle interventions for adults with obesity or overweight with weight-related complications who have had an inadequate response to lifestyle interventions alone.

Practitioners should consider pharmacologic options for patients not responding to lifestyle changes.

Incretin analogs (liraglutide, semaglutide, and tirzepatide) are effective for weight management in adults without diabetes, with percent weight loss ranging from 5.7% to 20.9%.

Healthcare providers can consider prescribing these agents for weight management in overweight or obese patients without diabetes.

GLP-1 receptor agonists provide glycemic and complication-risk reduction benefits for individuals with type 2 diabetes.

Practitioners can consider GLP-1 receptor agonists as effective treatment options for managing glycemic levels and reducing complications in type 2 diabetes patients.

CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.

Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.

Obesity is a major contributor to type 2 diabetes, necessitating medication management for both conditions.

Addressing obesity is crucial in managing type 2 diabetes, and medication may be necessary.

Weight-loss medications, especially incretin mimetics, are effective for short- and long-term treatment of obesity-related hypertension.

Practitioners may consider prescribing incretin mimetics for effective management of obesity-related hypertension.

Surgical treatment of obesity achieves the greatest long-term weight loss compared to conservative treatment.

Practitioners should consider surgical options for patients seeking significant long-term weight loss.

Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes.

Healthcare providers may consider glucagon-like peptide-1 receptor agonists as a treatment option for obesity and diabetes risk reduction.

The category of weight loss had significantly greater decreases in hunger and increases in flexible dietary restraint compared to the categories of weight stability and weight gain.

Weight loss may be associated with improved hunger management and dietary restraint.

Treatment proposals for obesity must be individualized according to phenotyping.

Tailoring obesity treatment plans to individual profiles can enhance effectiveness.

Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes.

Practitioners can consider GLP-1 receptor agonists as effective treatments for weight management and gastrointestinal health.

Bariatric interventions have shown the best therapeutic benefits in individuals with obesity.

Bariatric interventions should be considered as a primary treatment option for obesity.